Trial Profile

A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adagrasib (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Sponsors Mirati Therapeutics

Most Recent Events

19 May 2023 Number of treatment arms have been increased from 2 to 3 by the addition of Experimental: Cohort E arm. Pemetrexed, Cisplatin/Carboplatin have also been added to chemotherapy to be given along with study drug.
19 May 2023 Planned End Date changed from 23 Dec 2025 to 1 Dec 2026.
19 May 2023 Planned primary completion date changed from 23 Jun 2025 to 1 Jun 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com